Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishal Bhatnagar

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2024
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational SymposiumJason Fangusaro, Robert A Avery, Michael J Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work GroupR Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
BMC Medical Research Methodology|August 8, 2025
Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignanciesGita Thanarajasingam, Vishal Bhatnagar, Brie N Noble, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> AlterationsAsma Dilawari, James Buturla, Christy Osgood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent AnemiaNina Kim, E Dianne Pulte, Lori A Ehrlich, et al.
BMJ Open|January 10, 2024
Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort studyGita Thanarajasingam, Paul Kluetz, Vishal Bhatnagar, et al.
The Lancet. Oncology|February 1, 2023
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working groupClaire Piccinin, Ethan Basch, Vishal Bhatnagar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2024
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational SymposiumJason Fangusaro, Robert A Avery, Michael J Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work GroupR Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
BMC Medical Research Methodology|August 8, 2025
Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignanciesGita Thanarajasingam, Vishal Bhatnagar, Brie N Noble, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> AlterationsAsma Dilawari, James Buturla, Christy Osgood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent AnemiaNina Kim, E Dianne Pulte, Lori A Ehrlich, et al.
BMJ Open|January 10, 2024
Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort studyGita Thanarajasingam, Paul Kluetz, Vishal Bhatnagar, et al.
The Lancet. Oncology|February 1, 2023
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working groupClaire Piccinin, Ethan Basch, Vishal Bhatnagar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
Pageof 8